Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177182 | 0.87 | SLC5A2 (0.71) | SLC5A2SLC5A1 | |
| SCHEMBL15836914 | 0.85 | SLC5A2 (0.62) | SLC5A2SLC5A1 | |
| SCHEMBL20211016 | 0.85 | SLC5A2 (0.62) | SLC5A2SLC5A1 | |
| SCHEMBL15822612 | 0.83 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL15822614 | 0.83 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL15297954 | 0.82 | SLC5A2 (0.69) | SLC5A2 | |
| SCHEMBL15836715 | 0.82 | SLC5A2 (0.77) | SLC5A2 | |
| SCHEMBL18020612 | 0.82 | SLC5A2 (0.77) | SLC5A2 | |
| SCHEMBL26764578 | 0.81 | SLC5A2 (0.84) | SLC5A2 | |
| SCHEMBL15297956 | 0.81 | SLC5A2 (0.84) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | SLC5A2 1033/4885SLC5A1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.